

## STANDARD TREATMENT WORKFLOW (STW)

# Urticaria and Angioedema

Binod K Khaitan<sup>1</sup>, Deepika Pandhi<sup>2</sup>, Ananta Khurana<sup>3</sup>, Dipankar De<sup>4</sup>, Rahul Mahajan<sup>5</sup>, Renu George<sup>6</sup>, Vishal Gupta<sup>7</sup>

<sup>1</sup>All India Institute of Medical Sciences, New Delhi; <sup>2</sup>University College of Medical Sciences, New Delhi; <sup>3</sup>Dr. Ram Manohar Lohia Hospital, New Delhi; <sup>4</sup>Postgraduate Institute of Medical Education and Research, Chandigarh; <sup>5</sup>Postgraduate Institute of Medical Education and Research, Chandigarh; <sup>6</sup> Christian Medical College, Vellore; <sup>7</sup>All India Institute of Medical Sciences, New Delhi

### CORRESPONDING AUTHOR

Dr Binod K Khaitan, Department of Dermatology, All India Institute of Medical Sciences, New Delhi  
Email: [binodkhaitan@hotmail.com](mailto:binodkhaitan@hotmail.com)

### CITATION

Khaitan BK, Pandhi D, Khurana A, De D, Mahajan R, George R, Gupta V. Urticaria and Angioedema. Journal of the Epidemiology Foundation of India. 2024;2(1Suppl):S99-S100.

DOI: <https://doi.org/10.56450/JEFI.2024.v2i1Suppl.050>

*This work is licensed under a Creative Commons Attribution 4.0 International License.*

*@The Author(s). 2024 Open Access*

### DISCLAIMER

This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.

July/2024



Department of Health Research  
Ministry of Health and Family Welfare, Government of India



icmr  
INDIAN COUNCIL OF  
MEDICAL RESEARCH  
Securing the nation since 1911

## Standard Treatment Workflow (STW)

# URTICARIA AND ANGIOEDEMA

ICD-10-L50.9

URTICARIA-CLINICAL APPEARANCE		HISTORY	
<ul style="list-style-type: none"><li>• <b>Urticaria</b> -sudden appearance of wheals, angioedema, or both</li><li>• <b>A wheal</b>- A sharply circumscribed superficial central swelling of variable size and shape, surrounded by reflex erythema<ul style="list-style-type: none"><li>• Associated with itching /burning sensation and of fleeting nature- resolves within 1–24 hours</li><li>• Chronic urticaria implies duration for more than 6 weeks</li></ul></li><li>• <b>Angioedema</b><ul style="list-style-type: none"><li>• Sudden, pronounced, erythematous or skin-colored swelling of lower dermis and subcutis with frequent involvement of mucous membranes</li><li>• Associated pain, rather than itching /resolution is slower and can take up to 72 hours</li></ul></li></ul>	<ul style="list-style-type: none"><li>• Time to onset</li><li>• Frequency / duration</li><li>• Diurnal variation</li><li>• Associated angioedema</li><li>• Associated pain, itch</li><li>• Induction by physical agents or exercise</li><li>• Family history</li><li>• Previous allergies</li><li>• Surgical implantations</li><li>• Gastric / intestinal problem</li></ul>	<ul style="list-style-type: none"><li>• Drug history</li><li>• Correlation with food</li><li>• Correlation with menses</li><li>• Smoking</li><li>• Work profile</li><li>• Hobbies</li><li>• Stress</li><li>• Quality of life impact</li><li>• Response to therapy</li></ul>	
CLASSIFICATION OF CHRONIC URTICARIA SUBTYPES (presenting with wheals, angioedema, or both)		EXAMINATION	
<b>Chronic spontaneous</b> <ul style="list-style-type: none"><li>• Spontaneous appearance of wheals, angioedema, or both for <math>\geq 6</math> weeks</li></ul>	<b>Inducible (mostly physical)</b> <ul style="list-style-type: none"><li>• Symptomatic dermatographism</li><li>• Delayed pressure urticaria</li><li>• Cholinergic urticaria</li><li>• Cold/Heat urticaria</li><li>• Solar urticaria</li><li>• Aquagenic urticaria</li><li>• Contact urticaria</li></ul>	<ul style="list-style-type: none"><li>• Due to evanescent nature the examination may not show any lesions</li><li>• Presence of wheals of various sizes and shapes</li><li>• The lesions are non-scaly but show an intense erythema and a trailing clearing region in older areas which may lead to a target configuration in expanding plaques</li></ul>	



## Standard Treatment Workflow (STW) URTICARIA AND ANGIOEDEMA ICD-10-L50.9

<b>URTICARIA-CLINICAL APPEARANCE</b> <ul style="list-style-type: none"> <li>• <b>Urticaria</b> -sudden appearance of wheals, angioedema, or both</li> <li>• <b>A wheal</b>- A sharply circumscribed superficial central swelling of variable size and shape, surrounded by reflex erythema                         <ul style="list-style-type: none"> <li>• Associated with itching / burning sensation and of fleeting nature- resolves within 1-24 hours</li> <li>• Chronic urticaria implies duration for more than 6 weeks</li> </ul> </li> <li>• <b>Angioedema</b> <ul style="list-style-type: none"> <li>• Sudden, pronounced, erythematous or skin-colored swelling of lower dermis and subcutis with frequent involvement of mucous membranes</li> <li>• Associated pain, rather than itching /resolution is slower and can take up to 72 hours</li> </ul> </li> </ul>		<b>HISTORY</b> <ul style="list-style-type: none"> <li>• Time to onset</li> <li>• Frequency / duration</li> <li>• Diurnal variation</li> <li>• Associated angioedema</li> <li>• Associated pain, itch</li> <li>• Induction by physical agents or exercise</li> <li>• Family history</li> <li>• Previous allergies</li> <li>• Surgical implantations</li> <li>• Gastric / intestinal problem</li> </ul> <ul style="list-style-type: none"> <li>• Drug history</li> <li>• Correlation with food</li> <li>• Correlation with menses</li> <li>• Smoking</li> <li>• Work profile</li> <li>• Hobbies</li> <li>• Stress</li> <li>• Quality of life impact</li> <li>• Response to therapy</li> </ul>	
<b>CLASSIFICATION OF CHRONIC URTICARIA SUBTYPES (presenting with wheals, angioedema, or both)</b>		<b>EXAMINATION</b>	
<b>Chronic spontaneous</b> <ul style="list-style-type: none"> <li>• Spontaneous appearance of wheals, angioedema, or both for <math>\geq 6</math> weeks</li> </ul>	<b>Inducible (mostly physical)</b> <ul style="list-style-type: none"> <li>• Symptomatic dermographism</li> <li>• Delayed pressure urticaria</li> <li>• Cholinergic urticaria</li> <li>• Cold/Heat urticaria</li> <li>• Solar urticaria</li> <li>• Aquagenic urticaria</li> <li>• Contact urticaria</li> </ul>	<ul style="list-style-type: none"> <li>• Due to evanescent nature the examination may not show any lesions</li> <li>• Presence of wheals of various sizes and shapes</li> <li>• The lesions are non-scaly but show an intense erythema and a trailing clearing region in older areas which may lead to a target configuration in expanding plaques</li> </ul>	

### DIFFERENTIAL DIAGNOSES OF URTICARIA

<ul style="list-style-type: none"> <li>• Insect /Bedbug bites</li> <li>• Urticarial vasculitis- painful, persist for 24-48 hours and fade to leave bruising; <math>\pm</math> fever and arthralgia</li> <li>• Pre bullous phase of bullous pemphigoid</li> <li>• Maculopapular drug/ viral rash</li> </ul>		
	<b>URTICARIA</b>	<b>URTICARIAL VASCULITIS</b>

### INVESTIGATIONS

<b>INVESTIGATIONS</b> <p><b>Generally, no investigations are needed to confirm the diagnosis</b></p> <ul style="list-style-type: none"> <li>• Skin biopsy may be indicated if other diagnoses are being suspected</li> <li>• C4 and C1 inhibitor quantitation to detect C1 inhibitor deficiency may be done in suspected hereditary angioedema (Angioedema without urticaria)</li> <li>• Tests for current or past viral, bacterial or parasitic infections should be guided by history and clinical findings</li> <li>• Lab tests may be needed if patient is planned for immunosuppressive treatment</li> <li>• <b>Certain investigations that are often ordered, but are of limited utility</b> <ul style="list-style-type: none"> <li>• Thyroid function tests and antithyroid peroxidase (TPO) antibodies</li> <li>• Autologous serum skin test (ASST)</li> <li>• Skin prick / specific IgE test</li> </ul> </li> </ul>	<b>GENERAL PRINCIPLES</b> <ul style="list-style-type: none"> <li>• Reassure -remits spontaneously in 12-24 months in ~50% patients</li> <li>• Treat with antihistamines. Reassure that prolonged treatment with long-acting, non-sedating antihistamines is not harmful</li> <li>• Non-sedating antihistamines (e.g. Cetirizine 10mg, Levocetirizine 5mg, Loratadine 10mg, or Fexofenadine 180mg once daily) mainstay of treatment. Dose can be increased 4-fold safely if needed</li> <li>• Long-term first generation antihistamines e.g. Chlorphenamine, Hydroxyzine avoided if possible due to risk of sedation and psychomotor impairment</li> <li>• Avoid triggers including drugs such as NSAIDs, PCM, ACE inhibitors if history is suggestive of drug induced or exacerbated urticaria/ angioedema</li> </ul>
---	---

### TREATMENT

<b>TREATMENT OF URTICARIA/ANGIOEDEMA* AT PRIMARY CARE LEVEL</b> <p><b>First Line:</b> 2nd generation non-sedating antihistamines</p> <p><i>If symptoms persist after 2 weeks</i></p> <p><b>Second Line:</b> Increase dosage (upto fourfold) of 2nd generation antihistamines</p> <p><i>If symptoms persist after 2-4 further weeks</i></p> <p><b>Refer to higher centre</b></p>	<ul style="list-style-type: none"> <li>• Severe urticaria with respiratory distress- maintain airway; injectable Hydrocortisone and Pheniramine (Avil) may be required</li> <li>• Intra-muscular Adrenaline of 1:1000 dilution (1 mg in 1 mL), 0.2 to 0.5 mg (0.01 mg/kg in children; maximum dose: 0.3 mg) administered intramuscularly every 5 to 15 minutes if choking/respiratory distress/shock</li> <li>• <i>Angioedema with respiratory or laryngeal symptom requires emergency management -refer to higher center after vital stabilization; oral Prednisolone may be initiated to take care of biphasic response</i></li> </ul>	<b>REFER TO A HIGHER CENTRE</b> <ul style="list-style-type: none"> <li>• Patients whose urticaria is difficult to control with antihistamines despite fourfold higher dosage than the licensed doses of Cetirizine, Levocetirizine or Fexofenadine</li> <li>• Patients with polypharmacy</li> <li>• Unusual urticaria e.g. long lasting lesions &gt;24-48 hours with bruising</li> <li>• Associate angioedema that is unresponsive or presents with choking/ dyspnoea</li> <li>• Investigations not available</li> </ul>
<b>MANAGEMENT AT SECONDARY CARE LEVEL</b> <p><b>First Line:</b> 2nd generation antihistamines</p> <p><i>If symptoms persist after 2 weeks</i></p> <p><b>Second Line:</b> Increase dosage (upto fourfold) of 2nd generation antihistamines</p> <p><i>If symptoms persist after 2-4 further weeks</i></p> <p><b>Add third line on to second line:</b> Cyclosporine A (3-5 mg/Kg) or Montelukast (10 mg HS) Short course (max 10 days) of corticosteroids (Prednisolone-0.3-0.5 mg/kg)*</p>	<b>MANAGEMENT AT TERTIARY CARE LEVEL</b> <p><b>First Line:</b> 2nd generation antihistamines</p> <p><i>If symptoms persist after 2 weeks</i></p> <p><b>Second Line:</b> Increase dosage (upto fourfold) of 2nd generation antihistamines</p> <p><i>If symptoms persist after 2-4 further weeks</i></p> <p><b>Third line:</b> Add on to second line Omalizumab (300mg s/c every 4 weeks) or Cyclosporine A or Montelukast Short course (max 10 days) of corticosteroids*</p>	

\*Oral or injectable corticosteroids are generally not used, except in uncontrolled disease or with associated respiratory symptoms

### URTICARIA TREATMENT GOAL IS DISEASE REMISSION-NOT CURE

This STW has been prepared by national experts of India with feasibility considerations for various levels of health care system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information: ([stw.icmr.org.in](http://stw.icmr.org.in)) for more information.  
©Department of Health Research, Ministry of Health & Family Welfare, Government of India.